Previous 10 | Next 10 |
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Iovance Biotherapeutics (IOVA) drops 5.1% premarket after announcing clinical data for its tumor infiltrating lymphocyte ((TIL)) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC). The overall response rate ((ORR)) was 21.4% (n=28, one complete response a...
DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management wil...
Instil Bio (TIL): Q1 GAAP EPS of -$0.66 beats by $0.02.As of March 31, 2021, cash and cash equivalents totaled $609.6M.Press Release For further details see: Instil Bio EPS beats by $0.02
IPO in March 2021 raising $368M in gross proceeds Received orphan drug designation from the U.S. FDA for lead product candidate ITIL-168 DALLAS, May 13, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical com...
At the mid-April American Association of Cancer Research Annual Meeting, bleeding-edge oncology company Instil Bio (NASDAQ: TIL) reported promising results for one of its candidate therapies. In a compassionate-use program, the company's tumor-infiltrating lymphocyte (TIL) thera...
Instil Bio (TIL) has added ~7.0% in the pre-market after announcing that the FDA has granted the orphan drug designation for the treatment of melanoma stages IIB to IV with its ITIL-168 TIL therapy.The orphan drug title enables the drug’s developers to claim benefit...
DALLAS, April 27, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of melanoma stages IIB to IV with its ITIL-168 TIL therapy. “The Orphan D...
67% overall response rate and 19% complete response rate in 21 patients All complete responders remained in remission at time of data cut-off DALLAS, April 12, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceuti...
DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer, today announced the closing of it...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update. Recent...